MarjorieGlassZaudererMDMS

Oncology • Hawthorne, NY

Associate Attending Thoracic Oncology Service Co-Director MSK Mesothelioma Program MSKCC

Join to view full profile

Dr. Zauderer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Zauderer's full profile

Already have an account?

Office
19 Bradhurst Ave
Ste 2100N
Hawthorne, NY 10532
Phone+1 914-493-8375

Fax+1 914-347-1832

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2006 - 2009
Columbia University Vagelos College of Physicians and SurgeonsClass of 2006

Certifications & Licensure

FL State Medical License 2021 - Present
CT State Medical License 2023 - 2025
NJ State Medical License 2019 - 2025
NY State Medical License 2007 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

Clinical and Histopathologic Characteristics of BAP1 Mutations Start of enrollment: 2013 Jan 01
Completed
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin Start of enrollment: 2015 May 01
Active, not recruiting
Phase 1, Phase 2
Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma Start of enrollment: 2017 Oct 05
Terminated
Phase 1, Phase 2
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma Start of enrollment: 2019 Jul 24
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

260 citations
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.
Bastien Nguyen, Christopher Fong, Anisha Luthra, Shaleigh A Smith, Renzo G DiNatale
Cell. 2022-02-03
2 citations
The BAP1 nuclear deubiquitinase is involved in the nonhomologous end-joining pathway of double-strand DNA repair through interaction with DNA-PK.
Hiroki Sato, Tatsuo Ito, Takuo Hayashi, Shigehisa Kitano, Hediye Erdjument-Bromage
Oncogene. 2024-04-01
43 citations
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study.
Marjorie G Zauderer, Peter W Szlosarek, Sylvestre Le Moulec, Sanjay Popat, Paul Taylor
The Lancet. Oncology. 2022-06-01

Lectures

Association of BAP1 alterations with malignant pleural mesothelioma treated with trimodality therapy.
2019 ASCO Annual Meeting - 6/1/2019
Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactiva...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

MSK Research Highlights, November 23, 2022November 23rd, 2022
MARF to Host International Symposium on Malignant MesotheliomaJuly 20th, 2022
‘Promising’ Durvalumab Results Spark Phase 3 Trial in MesotheliomaJune 4th, 2020
Join now to see all